Low expression of ARHI is associated with shorter progression-free survival in pancreatic endocrine tumors

Irene Dalai, Edoardo Missiaglia, Stefano Barbi, Giovanni Butturini, Claudio Doglioni, Massimo Falconi, Aldo Scarpa

Research output: Contribution to journalArticle


Little is known about the molecular anomalies involved in the development and progression of malignancy of pancreatic endocrine tumors (PETs). A recently identified member of the Ras family, Ras homologue member I (ARHI ), has been shown to be involved in breast, ovary, and thyroid carcinogenesis. Unlike other members, it acts as a tumor suppressor gene that inhibits cell growth. Here we analyzed the mRNA expression of ARHI in 52 primary PETs and 16 normal pancreata using quantitative reverse transcription-polymerase chain reaction. ARHI expression showed a statistically significant difference between either normal pancreas or well-differentiated endocrine tumors (WDET) and poorly differentiated endocrine carcinomas (PDECs) (P <.001 and P <.001, respectively). Moreover, ARHI expression among WDEC samples was more heterogeneous than in WDET, with several tumors showing level of expression analogous to that observed in PDECs. A significant correlation between lower ARHI expression and shorter survival (P = .020) was identified, and a low ARHI expression was associated to a shorter time to progression (P <.001), even considering the proliferation index Ki67 in the multivariate analysis. ARHI is involved in PET progression. Its mRNA expression seemed to be a prognostic factor for disease outcome and, in association with the proliferative index Ki67, a predictor for a rapid tumor relapse.

Original languageEnglish
Pages (from-to)181-183
Number of pages3
JournalNeoplasia (United States)
Issue number3
Publication statusPublished - Mar 2007



  • ARHI
  • Pancreatic endocrine tumor
  • Survival
  • Time to progression
  • Tumor differentiation

ASJC Scopus subject areas

  • Cancer Research

Cite this